Advertisement

Advertisement
Multiple Myeloma

Is Autologous Hematopoietic Stem Cell Transplant Safe and Effective for Patients Aged 70 or Older With Multiple Myeloma?

Even though autologous hematopoietic stem cell transplantation (AHCT) is an effective treatment for multiple myeloma, only 4 out of 10 patients receive this therapy. A new study presented by Munshi et al at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 782) has shown AHCT is safe and effective in older patients, and suggests that more people could benefit from the therapy than have typically been offered it. 

Lymphoma
Immunotherapy

CAR T-Cell Therapy Shows Activity, Reduces Health-Care Utilization in Older Patients With DLBCL

A new analysis of Medicare claims data presented by  Kilgore et al at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 793) has provided the first real-world evidence using claims data available after the approval of autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. These analyses showed that CAR T-cell therapy can be beneficial for a broad population of older patients with diffuse large B-cell lymphoma (DLBCL), including those with multiple chronic conditions. The research also showed patients spent less time in the hospital and had lower health-care costs after CAR T-cell therapy than they did in the months leading up to it.

Prostate Cancer
Issues in Oncology

Sequence of Therapies for Metastatic Castration-Resistant Prostate Cancer

This week on The ASCO Post Podcast, we discuss a trial focused on the sequence of therapies for metastatic, castration-resistant prostate cancer. Then, we move on to an abstract presented at a recent American Heart Association meeting about the link between increased cardiovascular disease risk and increased cancer risk. Lastly, we give you an update about the latest step in the confirmation process for Dr. Stephen Hahn, the oncologist nominated to be the next FDA Commissioner.

 

 


Advertisement
Leukemia
Issues in Oncology

Lower Area-Based Income and Educational Attainment Associated With Poorer Survival Among Pediatric Patients With AML

Children from lower-income neighborhoods were 2.4 times more likely to die during treatment for acute myeloid leukemia (AML) than children from middle- and high-income neighborhoods, according to findings from a study that analyzed nearly 1,500 clinical trial participants. While previous research has pointed to racial disparities in cancer survival, the new study is the first to identify socioeconomic status as a key contributor to disparities among children with AML who were enrolled in clinical trials. These results were presented by Winestone et al at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 703).

Leukemia
Myelodysplastic Syndromes

Early-Phase Study of Venetoclax in Reduced-Intensity Transplant Conditioning Regimen for Patients With High-Risk Myeloid Malignancies

For patients with high-risk myeloid malignancies undergoing allogeneic hematopoietic stem cell transplant, adding the BCL-2 inhibitor venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to engraft. The phase I study was presented by Garcia et al at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 258).The findings provide support for the use of venetoclax prior to transplant as a way to increase the chances of transplant success in this group of patients, said first study author Jacqueline S. Garcia, MD, of Dana-Farber Cancer Institute.

Advertisement




More Top Stories

Hepatobiliary Cancer

Angela Lamarca, MD, PhD, on Liver Metastases From Intrahepatic Cholangiocarcinoma

Breast Cancer

ESMO Asia 2019: Trastuzumab Biosimilar HLX02 Shows Activity in HER2-Positive Metastatic Breast Cancer

The trastuzumab biosimilar HLX02—manufactured in China—achieved a similar overall response rate to reference trastuzumab in women with HER2-positive recurrent or previously untreated metastatic breast cancer, according to a large, randomized phase III study reported by Xu et al at the European...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Breast Cancer
Immunotherapy

Sherene Loi, MD, PhD, and Leisha A. Emens, MD, PhD, on HER2-Positive Breast Cancer: KATE2 Study of Atezolizumab/Trastuzumab Emtansine

Immunotherapy
Lymphoma

ASH 2019: Early Data Signal Potential for Bispecific Antibody in Non-Hodgkin Lymphoma

The investigational bispecific antibody mosunetuzumab is showing activity in preliminary studies of patients with non-Hodgkin lymphoma (NHL), including those who are refractory to or relapsed after third-line chimeric antigen receptor (CAR) T-cell therapy. If preliminary findings are validated by...

Cardiovascular Disease Risk May Be Associated With Cancer Risk

People with risk factors for cardiovascular diseases (determined by traditional risk, 10-year artherosclerotic cardiovascular disease risk score, and biomarkers) were also at higher risk for developing cancer compared to people with lower cardiovascular disease risk, according to research presented ...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Leukemia
Immunotherapy

Nitin Jain, MD, on CLL: Is There a Role for Chemoimmunotherapy?

Cardiovascular Disease Risk May Be Associated With Cancer Risk

People with risk factors for cardiovascular diseases (determined by traditional risk, 10-year artherosclerotic cardiovascular disease risk score, and biomarkers) were also at higher risk for developing cancer compared to people with lower cardiovascular disease risk, according to research presented ...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...